Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Maria Constantinou, Brown University
ClinicalTrials.gov Identifier:
NCT01650350
First received: July 24, 2012
Last updated: March 11, 2014
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2013
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)